Afuco™ Anti-TGFB1 ADCC Therapeutic Antibody (Metelimumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human TGFB1. Metelimumab is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-762 |
| Pricing | Inquiry |
| Host | Human |
| Target | TGFB1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FC, IP, ELISA, Neut, FuncS, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |